Drug utilization in the inpatient setting can provide a mechanism to assess drug prescribing trends, efficiency, and cost-effectiveness of hospital formularies and examine subpopulations for which prescribing habits may be different. Such data can be used to correlate trends with time-dependent or seasonal changes in clinical event rates or the introduction of new pharmaceuticals. It is now possible to provide a robust, dynamic analysis of drug utilization in a large pediatric inpatient setting through the creation of a Web-based hospital drug utilization system that retrieves source data from our accounting database. The production implementation provides a dynamic and historical account of drug utilization at the authors' institution. The existing application can easily be extended to accommodate a multiinstitution environment. The creation of a national or even global drug utilization network would facilitate the exami

D
rug utilization is an important component of many research initiatives that examine the effectiveness (clinical and economic) of pharmacotherapy applied in the inpatient, outpatient, and various specialty care settings. The application of drug utilization monitoring likewise provides further input into utilization correlation with medication effectiveness, prescribing habits, and time dependencies. Table I illustrates some of the more recent examples in which drug utilization has been examined as well as the objectives for these efforts. In the realm of pediatric pharmacotherapy, the investigation of drug utilization is used to examine numerous outcomes, including the examination of prescribing trends in various clinical settings, the extent to which best practices in children differ from drug monographs/labeling and adult dosing guidance, the cost-effectiveness of hospital formularies, and the correlation between medication errors and utilization. Thus, the research and investigation of drug utilization are evolving into an important pharmacoepidemiologic approach to improving patient care.
Many of the applications listed in Table I reflect targeted applications and measurement of utilization over a finite time window. Some reflect surveyed data gathering or data collected from paper-based medical records. These not only require a laborintensive effort for collection, data entry, and analysis but also imply a degree of uncertainty about the nature of the data, as well as the error associated with the various assembly stages. Others are supported by existing data stores that are used for other purposes (eg, pharmacy or accounting databases) and also necessitate information technology (IT) and programmatic support for data interface, extraction, and analysis. Most of these are likewise static in the sense that they do not represent committed systems to support the continued assessment of utilization. Our previous efforts to examine drug utilization at The Children' Due to the inability to collect these data electronically, database creation was dependent on a laborious manual entry over 6 months, prompting the development of a more sophisticated and reliable method to capture drug utilization. Information systems are required by the hospital administrative staff for planning and policy, as well as by clinicians for evaluation of process and outcomes of clinical care. Legacy hospital information systems, although providing adequate support for patient care and billing, are poorly suited for meeting the information needs of hospital management and research staff. Data requests from hospital research staff often cannot be serviced in a timely manner. In addition, hospital and clinical departmental systems installed at various times over the past 20 years are rarely compatible. Thus, creation of a data set suitable for analysis often demands time-consuming data manipulation such as conversion and merging.
Solutions to these problems include development of a central data warehouse or interface that performs real-time merges between disparate clinical information systems. Although each approach has its own merits and caveats, they often represent multiyear efforts, particularly given the continuously evolving hospitalbased landscape of IT hardware and supporting software systems. Our approach was to create a utilization-specific data mart by loading periodically spooled data files from our accounting database. The IT strategy was based on the desire to (1) leverage existing business processes and reporting tools to produce flat file data input, (2) produce a custom-built reporting module that allows for quick enhancement/addition of new reports and creation of new database entries and views, (3) perform a variety of interactive analyses, and (4) lower the total cost of ownership without expensive software licensing. Herein, we describe our hospital drug utilization (HDU) system, showing the initial functionality via typical queries of interest using data from the 2001 calendar year.
Our initial research objective was the assessment of drug utilization relative to previously described deficiencies in dosing guidance for various pediatric subpopulations. Our hypothesis was that this intersection would identify an important subset of drugs for which targeted clinical pharmacology investigation is warranted. We expect to also provide feedback from the HDU to other quality initiatives ongoing at our institution, which may ultimately improve medication errors. The purpose of this article is to describe the HDU system, illustrating the value of dynamic assessment of drug utilization across and within individual institutions. Such assessment will focus future pediatric pharmacologic investigation and ultimately address the medical needs of the patients being cared for at these institutions.
METHODS
Environment and Clinical Conduct
The Children's Hospital of Philadelphia (CHOP) Institutional Review Board (IRB) approved this study prior to the initiation of data collection. CHOP and its satellite locations handle more than 15 000 inpatient admissions annually and see more than 200 000 emergency and outpatient visits each year. The main hospital has 304 beds, 20% of which are allocated to intensive care. The Wood Ambulatory Care Center houses the hospital's outpatient specialty clinics. In addition, Children's Seashore House, a major rehabilitation facility for patients with chronic illnesses, lies adjacent to the hospital's outpatient facility. The system, as developed above, was populated with 1 year's (2001) worth of data. Each inpatient or outpatient visit/admission was considered a patient encounter, and therefore patients who were hospitalized more than once during 2001 were included for each separate encounter. Based on Food and Drug Administration (FDA) pediatric age criteria, patients were categorized as neonates (>0-1 month), infants (>1 month to 2 years), children (>2-12 years), adolescents (>12-16 years), young adults (>16-21 years), and adults (>21-110 years). The total number of patient encounters was calculated over the 2001 calendar year. The 25 most frequently prescribed medications in all patients were identified and expressed as the number of encounters exposed to an individual medication and as a percentage of the total number of encounters. In addition, the total number of individual medication administrations was calculated. These results were then further stratified based on age group. As an example of an interactive drug class query, benzodiazepine utilization was examined across age strata. A χ 2 analysis was used to determine differences in the utilization of various benzodiazepines. As another function of this application, the most frequently performed procedures were also assessed.
Architecture, Hardware, and Software Environment
The HDU system can be characterized as a 3-tier architecture anchored by a backend relational database.
The middle tier comprises Java objects required for data transformation rules, conversions, and so on. The presentation layer contains JSP/Javascript-driven Web pages (HDU output screens). The system separates the presentation content (data), presentation and layout (rendering), and logic controlling the application. A more detailed description of the HDU system architecture is available (http://stokes.chop.edu/ programs/cpt/hdu), and additional details are available upon request.
The
-GHz Intel
Xeon CPUs with 2 GB of RAM each. The size of the entire database for a 5-year period is <1 GB. This architecture provides a foundation to scale the system as the data volume and user demand increase.
Data Model
The data model is based on a "star schema," which enables analysis, retrieval, and reporting. The central table, commonly referred to as the "fact table," is where all key facts, measurements, or results are stored. This table is connected to a set of attribute tables, commonly referred to as "dimension tables," through which the fact tables are indexed or defined. Thus, the model provides an intuitive method of querying result or fact data in any dimension. The integrity of the data model is protected through the use of surrogate keys, which provides flexibility to accommodate changing business needs. The dimensions align with the 2 types of data file feeds supported: (1) master files and (2) data files. Master files supply reference information that could be used as either a "reference list" or checkpoint for metadata when loading the data files.
The logical model of the HDU informatics system is displayed in Figure 1 . As illustrated in the figure, the model consists of 4 factual tables, each connected by supporting dimension tables. The table "Admission Fact" contains details of the patient admission, disposition at admission, and the types of services performed at the time. Details from the diagnosis are captured into "Diagnosis Fact," ensuring treatments are captured in "Treatment Fact," whereas any procedures that are performed are captured in "Procedure Fact." The remainder of the data model elements are "Master" tables, with the exception of "Patient," which contains demographic details. The dimension tables include details of patient disposition, service codes/details, procedure codes/details, physician ID/details, treatment code/details (charge code), nursing station identification/details, and diagnosis codes/details.
Additional tables within the model support authentication, authorization, available reports, report details, summarization tables, audit logs, and so on. The user interface has been designed to dynamically update the reporting selector screens as when existing reports are modified or new reports added. Each report is either linked to an Oracle view or materialized view (snapshot tables) that provides preaggregated summaries. Collectively, the set of tables is designed for easy administration and management by a single, part-time technical resource.
Hospital Drug Utilization Interface and Report Selector
A report selector window with available reports from the database represents the initial access to the HDU once the user ID and password have been confirmed. The current list of prestructured queries and reports includes the following: total population, stratified by age group; top 25 drugs based on patient exposure; top 25 drugs based on patient exposure, stratified by age group; top 25 drugs based on drug administration; top 25 drugs based on drug administration, stratified by age, race, or gender; drug utilization by month, stratified by age group; top 25 procedures, stratified by age group; and top 25 procedures in tabular format. Each report is linked to a summary table in Oracle that provides preaggregated data across the categories and filters that are listed in the report definition. This allows for easy addition and removal of reports from the interface without changes in application programming. In this initial prototype, the user can select only one report at a time; however, the final version is expected to support selection of multiple report items for rendering. Upon selection and submission of the request, the report is rendered in a new window. The user can click on the BACK link and execute other reports any number of times. The displayed reports can be downloaded as an Excel data set or as images in a number of supported graphic file formats, including GIF, PNG, JPEG, or exported directly into MS Word.
ZUPPA ET AL
RESULTS
Clinical Applications
A total of 61 916 encounters were recorded in the 2001 calendar year for The Children's Hospital of Philadelphia, based on our accounting data records. The HDU system was used to capture demographic data as strata to summarize drug utilization as well. The partition of encounters by age strata was as follows: 1265 neonates (>0-1 month), 15 665 infants (>1 month to 2 years), 31 540 children (>2-12 years), 7801 adolescents (>12-16 years), 4884 young adults (>16-21 years), and 764 adults (>21-110 years). Infants and children constitute the 2 largest age groups being treated at CHOP (and its satellite locations) during 2001.
Drug utilization based on the number of encounters exposed to a specific medication is represented in Table II . In 2001, the most commonly used medications based on exposed encounters were acetaminophen and heparin. These data, stratified by age, are represented in Figure 2A . Drug utilization based on the total number of times a medication was administered is similarly listed in Table II . In 2001, sodium chloride was administered 280 949 times, whereas heparin was administered 220 160 times. Likewise, whereas Table II shows a good deal of correlation between the 2 utilization metrics, there are some differences as well. The relative merits of the various metrics used to describe utilization have not been explored at this time but will be the subject of future research based on data sets that span utilization over multiple years. The top 5 medications, stratified by gender, are represented in Figure 2B . The HDU system can be used to track drug utilization through user-selected time windows, to trend monthly/ seasonal differences. An example of this application is represented in Figure 3 , which shows the number of times acetaminophen was administered, stratified versions of the HDU will permit charting by class with drilldowns to individual agents. The most frequently performed procedures stratified by age are shown in Table III . Myringotomy with intubation was the most frequently performed procedure at CHOP in 2001. Again, intersections of diagnosis and procedures with various, related pharmacotherapeutic options are possible with the HDU. This environment can also be used to focus/refine further pediatric pharmacokinetic studies. For example, utilization for the 3 most commonly used benzodiazepines (diazepam, midazolam, and lorazepam) across the 4 pediatric age groups is represented in Figure 4 . There was a difference in utilization across these age groups for diazepam (P < .05), midazolam (P < .05), and lorazepam (P < .05). Lorazepam and diazepam were used most frequently in neonates. However, the use of benzodiazepines in this age group has been associated with adverse events, 2 and its pharmacokinetic evaluation in this age group is limited. 3 This example does not delineate specific indications for benzodiazepine selection. However, the final tool will have this capability. In any event, these applications demonstrate the potential of the HDU to answer targeted questions regarding pediatric pharmacotherapy.
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DISCUSSION
We describe the rationale and development of an HDU system, comprising a data mart and retrieval tool built and maintained via flat-file data feeds from a SEIMENS medical billing system. The preceding results illustrate the potential and value of such a tool. As this system is available online from any networked computer via a Web browser, it is extremely accessible and will interface with a variety of end users. The selection criteria for source data and frequency of updates have been carefully chosen to ensure that only curated data enter the HDU. The data mart is interfaced with a Web-based retrieval tool that allows users to review drug utilization trends across the institution, patient exposure to various drugs, the total number of drug administrations, seasonal variations in drug use, and demographics. The tool is simple, easy to use, and easy to maintain, thereby providing a convenient and cost-effective mechanism for accessing critical information in a timely manner. The system can be used for a variety of pharmacoepidemiologic purposes, including but not limited to compliance, quality assurance, and pharmacoeconomic analysis. Pharmacoeconomic assessments can be performed by linking practitioner preferences in drug utilization with specific procedures. A key benefit from our approach is the quick generation of meaningful reports by leveraging existing functionality and resources within the institution.
Knowledge of pediatric drug utilization continues to be an active area of investigation. Recent publications analyzing drug utilization in intensive care units 4, 5 do not include a methodology by which the dynamic assessment of utilization can be performed. Specialized data marts such as the HDU are critical to the evaluation of various aspects of patient care; The Children's Hospital of Philadelphia has several such efforts in place as part of an enterprise-wide initiative for the creation of centralized data warehousing and reporting tools. Many obstacles, such as difficulties with nursing charting (medications administered vs medications prescribed), data standardization, analytic tools, metrics of evaluation, and platform scalability, exist and must be overcome. A centralized, hospital-wide data warehouse will provide the source data for next-generation solution, and our pediatric knowledge-base initiative (http://stokes.chop.edu/programs/cpt/pkb) will further exploit utilization data against patient medical records and outcomes.
This user-friendly interface allows the clinical pharmacologist to assess utilization trends within an institution. This ability serves many purposes. For example, from a pharmacoeconomic perspective, examination of variability in practitioner-specific treatment of uniform diagnoses could standardize the treatment approach of common disorders. Another example is the assessment of legislative initiatives, including the Best Pharmaceuticals for Children's Act (BPCA), on prescribing trends within the institution. Practitioner preference often drives the choice of pharmacotherapy. Therefore, institutional needs may not always align with national pharmacologic endeavors. Therefore, clinical pharmacologists could identify the specific treatment groups that are subject to the lack of pediatric dosing guidance and focus investigator-initiated trials to obtain pharmacokinetic and pharmacodynamic data and improve drug delivery to these children. From a larger perspective, the implementation of a system similar to the HDU at individual institutions would allow these institutions to "talk" to one another. Efforts carried out at the institutional level could be brought to a more national level. This overview of pediatric pharmacotherapy, this true assessment of what types of medications children are receiving, is the vital foundation of future pharmacologic study.
With the creation of the BPCA priority list, the National Institute of Child Health and Human Development (NICHD) has been mandated to define the frequency of drug administration in the pediatric population, the severity of the condition being treated, and the potential for providing a health benefit in the pediatric population. 6 Because resources to perform clinical pharmacokinetic studies are limited, it is crucial to identify the most commonly prescribed drugs used to care for children and target these drugs for future study. However, there is insufficient knowledge about what these drugs are and how much clinical pharmacologic evidence supports their use in children. Without this information, no evidence-based and validated tool can be developed to appropriately direct and prioritize the study of these vital drugs. Thus, it will be important to develop a tool that can assess prescribing patterns in a pediatric hospital setting and ultimately across institutions throughout the United States. National and ultimately global utilization assessment is likewise a realistic vision and not a fantasy.
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